Cargando…

Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages

SIMPLE SUMMARY: Previous analyses from referral centers of testicular cancer investigated the prognostic impact of presence of teratoma components in advanced testicular primary tumor specimens and observed conflicting results. However, data investigating pure teratoma in primary tumor specimens is...

Descripción completa

Detalles Bibliográficos
Autores principales: Cano Garcia, Cristina, Barletta, Francesco, Incesu, Reha-Baris, Piccinelli, Mattia Luca, Tappero, Stefano, Panunzio, Andrea, Tian, Zhe, Saad, Fred, Shariat, Shahrokh F., Antonelli, Alessandro, Terrone, Carlo, De Cobelli, Ottavio, Graefen, Markus, Tilki, Derya, Briganti, Alberto, Wenzel, Mike, Banek, Severine, Kluth, Luis A., Chun, Felix K. H., Karakiewicz, Pierre I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913474/
https://www.ncbi.nlm.nih.gov/pubmed/36765653
http://dx.doi.org/10.3390/cancers15030694
_version_ 1784885436449030144
author Cano Garcia, Cristina
Barletta, Francesco
Incesu, Reha-Baris
Piccinelli, Mattia Luca
Tappero, Stefano
Panunzio, Andrea
Tian, Zhe
Saad, Fred
Shariat, Shahrokh F.
Antonelli, Alessandro
Terrone, Carlo
De Cobelli, Ottavio
Graefen, Markus
Tilki, Derya
Briganti, Alberto
Wenzel, Mike
Banek, Severine
Kluth, Luis A.
Chun, Felix K. H.
Karakiewicz, Pierre I.
author_facet Cano Garcia, Cristina
Barletta, Francesco
Incesu, Reha-Baris
Piccinelli, Mattia Luca
Tappero, Stefano
Panunzio, Andrea
Tian, Zhe
Saad, Fred
Shariat, Shahrokh F.
Antonelli, Alessandro
Terrone, Carlo
De Cobelli, Ottavio
Graefen, Markus
Tilki, Derya
Briganti, Alberto
Wenzel, Mike
Banek, Severine
Kluth, Luis A.
Chun, Felix K. H.
Karakiewicz, Pierre I.
author_sort Cano Garcia, Cristina
collection PubMed
description SIMPLE SUMMARY: Previous analyses from referral centers of testicular cancer investigated the prognostic impact of presence of teratoma components in advanced testicular primary tumor specimens and observed conflicting results. However, data investigating pure teratoma in primary tumor specimens is limited and the prognostic impact is uncertain. To address this void, we tested for overall survival differences and subsequently, differences in cancer-specific and other-cause mortality in pure teratoma vs. mixed germ cell tumor patients. ABSTRACT: We aimed to test for survival differences between testicular pure teratoma vs. mixed germ cell tumor (GCT) patients in a stage-specific fashion. Pure teratoma and mixed GCT in primary tumor specimens were identified within the Surveillance, Epidemiology, and End Results database (2004–2019). Kaplan–Meier curves depicted five-year overall survival (OS) and subsequently, cumulative incidence plots depicted cancer-specific mortality (CSM) and other-cause mortality (OCM) in a stage-specific fashion. Multivariable competing risks regression (CRR) models were used. Of 9049 patients, 299 (3%) had pure teratoma. In stage I, II and III, five-year OS rates differed between pure teratoma and mixed GCT (stage I: 91.6 vs. 97.2%, p < 0.001; stage II: 100 vs. 95.9%, p < 0.001; stage III: 66.8 vs. 77.8%, p = 0.021). In stage I, survival differences originated from higher OCM (6.4 vs. 1.2%; p < 0.001). Conversely in stage III, survival differences originated from higher CSM (29.4 vs. 19.0%; p = 0.03). In multivariable CRR models, pure teratoma was associated with higher OCM in stage I (Hazard Ratio (HR): 4.83; p < 0.01). Conversely, in stage III, in multivariable CRR models, pure teratoma was associated with higher CSM (HR: 1.92; p = 0.04). In pure teratoma, survival disadvantage in stage I patients relates to OCM. Survival disadvantage in stage III pure teratoma originates from higher CSM.
format Online
Article
Text
id pubmed-9913474
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99134742023-02-11 Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages Cano Garcia, Cristina Barletta, Francesco Incesu, Reha-Baris Piccinelli, Mattia Luca Tappero, Stefano Panunzio, Andrea Tian, Zhe Saad, Fred Shariat, Shahrokh F. Antonelli, Alessandro Terrone, Carlo De Cobelli, Ottavio Graefen, Markus Tilki, Derya Briganti, Alberto Wenzel, Mike Banek, Severine Kluth, Luis A. Chun, Felix K. H. Karakiewicz, Pierre I. Cancers (Basel) Article SIMPLE SUMMARY: Previous analyses from referral centers of testicular cancer investigated the prognostic impact of presence of teratoma components in advanced testicular primary tumor specimens and observed conflicting results. However, data investigating pure teratoma in primary tumor specimens is limited and the prognostic impact is uncertain. To address this void, we tested for overall survival differences and subsequently, differences in cancer-specific and other-cause mortality in pure teratoma vs. mixed germ cell tumor patients. ABSTRACT: We aimed to test for survival differences between testicular pure teratoma vs. mixed germ cell tumor (GCT) patients in a stage-specific fashion. Pure teratoma and mixed GCT in primary tumor specimens were identified within the Surveillance, Epidemiology, and End Results database (2004–2019). Kaplan–Meier curves depicted five-year overall survival (OS) and subsequently, cumulative incidence plots depicted cancer-specific mortality (CSM) and other-cause mortality (OCM) in a stage-specific fashion. Multivariable competing risks regression (CRR) models were used. Of 9049 patients, 299 (3%) had pure teratoma. In stage I, II and III, five-year OS rates differed between pure teratoma and mixed GCT (stage I: 91.6 vs. 97.2%, p < 0.001; stage II: 100 vs. 95.9%, p < 0.001; stage III: 66.8 vs. 77.8%, p = 0.021). In stage I, survival differences originated from higher OCM (6.4 vs. 1.2%; p < 0.001). Conversely in stage III, survival differences originated from higher CSM (29.4 vs. 19.0%; p = 0.03). In multivariable CRR models, pure teratoma was associated with higher OCM in stage I (Hazard Ratio (HR): 4.83; p < 0.01). Conversely, in stage III, in multivariable CRR models, pure teratoma was associated with higher CSM (HR: 1.92; p = 0.04). In pure teratoma, survival disadvantage in stage I patients relates to OCM. Survival disadvantage in stage III pure teratoma originates from higher CSM. MDPI 2023-01-23 /pmc/articles/PMC9913474/ /pubmed/36765653 http://dx.doi.org/10.3390/cancers15030694 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cano Garcia, Cristina
Barletta, Francesco
Incesu, Reha-Baris
Piccinelli, Mattia Luca
Tappero, Stefano
Panunzio, Andrea
Tian, Zhe
Saad, Fred
Shariat, Shahrokh F.
Antonelli, Alessandro
Terrone, Carlo
De Cobelli, Ottavio
Graefen, Markus
Tilki, Derya
Briganti, Alberto
Wenzel, Mike
Banek, Severine
Kluth, Luis A.
Chun, Felix K. H.
Karakiewicz, Pierre I.
Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages
title Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages
title_full Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages
title_fullStr Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages
title_full_unstemmed Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages
title_short Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages
title_sort survival of testicular pure teratoma vs. mixed germ cell tumor patients in primary tumor specimens across all stages
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913474/
https://www.ncbi.nlm.nih.gov/pubmed/36765653
http://dx.doi.org/10.3390/cancers15030694
work_keys_str_mv AT canogarciacristina survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT barlettafrancesco survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT incesurehabaris survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT piccinellimattialuca survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT tapperostefano survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT panunzioandrea survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT tianzhe survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT saadfred survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT shariatshahrokhf survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT antonellialessandro survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT terronecarlo survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT decobelliottavio survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT graefenmarkus survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT tilkiderya survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT brigantialberto survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT wenzelmike survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT banekseverine survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT kluthluisa survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT chunfelixkh survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages
AT karakiewiczpierrei survivaloftesticularpureteratomavsmixedgermcelltumorpatientsinprimarytumorspecimensacrossallstages